MedTrace Logo

Automated Insulin Delivery Amongst Pregnant Women With Type 1 Diabetes

NCT04938557 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2023-12-18

No results posted yet for this study

Summary

Evaluation of the biomedical and psychosocial impact of automated Closed-Loop (Artificial Pancreas) insulin delivery in women with type 1 diabetes during pregnancy

Conditions

Interventions

DEVICE

Automated closed-loop insulin delivery (AiD)

Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.

DEVICE

A standard insulin delivery system

Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.

Sponsors & Collaborators

  • University of East Anglia

    collaborator OTHER

  • University of Cambridge

    collaborator OTHER

  • University of Leeds

    collaborator OTHER

  • University of Edinburgh

    collaborator OTHER

  • University of Glasgow

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • Belfast Health and Social Care Trust

    collaborator OTHER

  • Norfolk and Norwich University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Helen Murphy · University of East Anglia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-26
Primary Completion
2022-04-30
Completion
2023-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04938557 on ClinicalTrials.gov